- Home
- AMRN vs CTNM Comparison
AMRN vs CTNM Comparison
Compare AMRN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- CTNM
- Stock Information
- Founded
- AMRN 1989
- CTNM 2009
- Country
- AMRN Ireland
- CTNM United States
- Employees
- AMRN N/A
- CTNM N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- CTNM
- Sector
- AMRN Health Care
- CTNM
- Exchange
- AMRN Nasdaq
- CTNM Nasdaq
- Market Cap
- AMRN 216.0M
- CTNM 248.7M
- IPO Year
- AMRN 1993
- CTNM 2024
- Fundamental
- Price
- AMRN $15.98
- CTNM $9.94
- Analyst Decision
- AMRN Strong Sell
- CTNM Strong Buy
- Analyst Count
- AMRN 1
- CTNM 4
- Target Price
- AMRN $12.00
- CTNM $22.75
- AVG Volume (30 Days)
- AMRN 69.5K
- CTNM 208.6K
- Earning Date
- AMRN 07-30-2025
- CTNM 08-05-2025
- Dividend Yield
- AMRN N/A
- CTNM N/A
- EPS Growth
- AMRN N/A
- CTNM N/A
- EPS
- AMRN N/A
- CTNM N/A
- Revenue
- AMRN $219,361,000.00
- CTNM N/A
- Revenue This Year
- AMRN N/A
- CTNM N/A
- Revenue Next Year
- AMRN N/A
- CTNM N/A
- P/E Ratio
- AMRN N/A
- CTNM N/A
- Revenue Growth
- AMRN N/A
- CTNM N/A
- 52 Week Low
- AMRN $7.08
- CTNM $3.35
- 52 Week High
- AMRN $17.49
- CTNM $20.55
- Technical
- Relative Strength Index (RSI)
- AMRN 59.78
- CTNM 79.45
- Support Level
- AMRN $15.54
- CTNM $6.56
- Resistance Level
- AMRN $16.50
- CTNM $6.95
- Average True Range (ATR)
- AMRN 0.48
- CTNM 0.82
- MACD
- AMRN 0.08
- CTNM 0.31
- Stochastic Oscillator
- AMRN 73.06
- CTNM 85.28
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.